These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 8964871)

  • 1. The human insulin analog insulin lispro improves insulin binding on circulating monocytes of intensively treated insulin-dependent diabetes mellitus patients.
    Jehle PM; Fussgaenger RD; Kunze U; Dolderer M; Warchol W; Koop I
    J Clin Endocrinol Metab; 1996 Jun; 81(6):2319-27. PubMed ID: 8964871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prolonged efficacy of short acting insulin Lispro in combination with human ultralente in insulin-dependent diabetes mellitus.
    Burge MR; Waters DL; Holcombe JH; Schade DS
    J Clin Endocrinol Metab; 1997 Mar; 82(3):920-4. PubMed ID: 9062507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of metabolic deterioration between insulin analog and regular insulin after a 5-hour interruption of a continuous subcutaneous insulin infusion in type 1 diabetic patients.
    Guerci B; Meyer L; Sallé A; Charrié A; Dousset B; Ziegler O; Drouin P
    J Clin Endocrinol Metab; 1999 Aug; 84(8):2673-8. PubMed ID: 10443658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of a short-acting insulin analog (Insulin Lispro) versus regular insulin on lipid metabolism in insulin-dependent diabetes mellitus.
    Caixàs A; Pérez A; Payés A; Otal C; Carreras G; Ordóñez-Llanos J; Reviriego J; Anderson JH; de Leiva A
    Metabolism; 1998 Apr; 47(4):371-6. PubMed ID: 9580247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic effects of mealtime insulin lispro in comparison to glibenclamide in early type 2 diabetes.
    Forst T; Eriksson JW; Strotmann HJ; Bai S; Brunelle R; Gulliya KS; Gack S; Gudat U
    Exp Clin Endocrinol Diabetes; 2003 Apr; 111(2):97-103. PubMed ID: 12746761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacodynamics of insulin Lispro in 2 patients with type II diabetes mellitus.
    Jehle PM; Fussgänger RD; Seibold A; Lüttke B; Böhm BO
    Int J Clin Pharmacol Ther; 1996 Nov; 34(11):498-503. PubMed ID: 8937933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Lispro analog and quality of life].
    Tubiana-Rufi N; Munz-Licha G
    Diabetes Metab; 1997 Sep; 23 Suppl 3():58-62. PubMed ID: 9410554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cessation of insulin infusion at night-time during CSII-therapy: comparison of regular human insulin and insulin lispro.
    Reichel A; Rietzsch H; Köhler HJ; Pfützner A; Gudat U; Schulze J
    Exp Clin Endocrinol Diabetes; 1998; 106(3):168-72. PubMed ID: 9710355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preprandial combination of lispro and NPH insulin improves overall blood glucose control in type 1 diabetic patients: a multicenter randomized crossover trial.
    Annuzzi G; Del Prato S; Arcari R; Bellomo Damato A; Benzi L; Bruttomesso D; Calderini MC; Coscelli C; Fedele D; Galluzzo A; Giordano M; Giorgino R; Lapolla A; Orsini P; Pagano G; Santoro D; Riccardi G
    Nutr Metab Cardiovasc Dis; 2001 Jun; 11(3):168-75. PubMed ID: 11590992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lispro insulin in type 1 diabetic patients on a Mediterranean or normal diet: a randomized, cross-over comparative study with regular insulin.
    Provenzano C; Vero R; Oliva A; Leto G; Puccio L; Vecci E; Mattioli PL; Di Mario U
    Diabetes Nutr Metab; 2001 Jun; 14(3):133-9. PubMed ID: 11476360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Lys(B28), Pro(B29)]-human insulin: effect of injection time on postprandial glycemia.
    Howey DC; Bowsher RR; Brunelle RL; Rowe HM; Santa PF; Downing-Shelton J; Woodworth JR
    Clin Pharmacol Ther; 1995 Oct; 58(4):459-69. PubMed ID: 7586939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Administration of Lispro insulin with meals improves glycemic control, increases circulating leptin, and suppresses ghrelin, compared with regular/NPH insulin in female patients with type 1 diabetes.
    Griffen SC; Oostema K; Stanhope KL; Graham J; Styne DM; Glaser N; Cummings DE; Connors MH; Havel PJ
    J Clin Endocrinol Metab; 2006 Feb; 91(2):485-91. PubMed ID: 16317063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of type 1 diabetes with insulin lispro during Ramadan.
    Kadiri A; Al-Nakhi A; El-Ghazali S; Jabbar A; Al Arouj M; Akram J; Wyatt J; Assem A; Ristic S
    Diabetes Metab; 2001 Sep; 27(4 Pt 1):482-6. PubMed ID: 11547222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunologic effects of insulin lispro [Lys (B28), Pro (B29) human insulin] in IDDM and NIDDM patients previously treated with insulin.
    Fineberg NS; Fineberg SE; Anderson JH; Birkett MA; Gibson RG; Hufferd S
    Diabetes; 1996 Dec; 45(12):1750-4. PubMed ID: 8922361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin lispro improves postprandial glucose control in patients with diabetes mellitus.
    Skrha J; Smahelová A; Andĕl M; Vrtovec M; Subić J; Kreze A; Vozar J; Korecová M; de Verga V; Wyatt J; Metcalfe S; Ristić S
    Sb Lek; 2002; 103(1):15-21. PubMed ID: 12448933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluctuations in the affinity and concentration of insulin receptors on circulating monocytes of obese patients: effects of starvation, refeeding, and dieting.
    Bar RS; Gorden P; Roth J; Kahn CR; De Meyts P
    J Clin Invest; 1976 Nov; 58(5):1123-35. PubMed ID: 993336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Efficacy of insulin Lispro in the control of late postprandial hypoglycemia: comparison with regular human insulin].
    Cotticelli G; Bartiromo D; Ciavattone A; Di Leva R; Porcaro G; Nascia S; Mastroianni M; Sannino C; Conti G
    Minerva Med; 2000; 91(7-8):147-52. PubMed ID: 11155463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential expression of receptors for advanced glycation end products on monocytes in patients with IDDM.
    Festa A; Schmölzer B; Schernthaner G; Menzel EJ
    Diabetologia; 1998 Jun; 41(6):674-80. PubMed ID: 9662049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subcutaneous injection of hyaluronidase with recombinant human insulin compared with insulin lispro in type 1 diabetes.
    Garg SK; Buse JB; Skyler JS; Vaughn DE; Muchmore DB
    Diabetes Obes Metab; 2014 Nov; 16(11):1065-9. PubMed ID: 24840317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparative study of insulin lispro and human regular insulin in patients with type 2 diabetes mellitus and secondary failure of oral hypoglycemic agents.
    Ross SA; Zinman B; Campos RV; Strack T;
    Clin Invest Med; 2001 Dec; 24(6):292-8. PubMed ID: 11767232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.